An Equivariant Pretrained Transformer for Unified 3D Molecular Representation Learning

TL;DR

This paper introduces EPT, a unified 3D molecular representation model that leverages cross-domain data and equivariant transformers, significantly improving performance in molecular and protein tasks and aiding drug discovery.

Contribution

The paper presents EPT, a novel all-atom, E(3)-equivariant transformer pretrained on diverse 3D molecular data, enabling cross-domain learning and superior downstream task performance.

Findings

EPT outperforms previous methods in ligand binding affinity prediction.

EPT achieves competitive results in protein and molecular property prediction.

EPT successfully identifies potential anti-COVID-19 drug candidates.

Abstract

Pretraining on a large number of unlabeled 3D molecules has showcased superiority in various scientific applications. However, prior efforts typically focus on pretraining models in a specific domain, either proteins or small molecules, missing the opportunity to leverage cross-domain knowledge. To mitigate this gap, we introduce Equivariant Pretrained Transformer (EPT), an all-atom foundation model that can be pretrained from multiple domain 3D molecules. Built upon an E(3)-equivariant transformer, EPT is able to not only process atom-level information but also incorporate block-level features (e.g. residuals in proteins). Additionally, we employ a block-level denoising task, rather than the conventional atom-level denoising, as the pretraining objective. To pretrain EPT, we construct a large-scale dataset of 5.89M entries, comprising small molecules, proteins, protein-protein complexes, and protein-molecule complexes. Experimental evaluations on downstream tasks including ligand binding affinity prediction, protein property prediction, and molecular property prediction, show that EPT significantly outperforms previous state-of-the-art methods in the first task and achieves competitively superior performance for the remaining two tasks. Furthermore, we demonstrate the potential of EPT in identifying small molecule drug candidates targeting 3CL protease, a critical target in the replication of SARS-CoV-2. Among 1,978 FDA-approved drugs, EPT ranks 7 out of 8 known anti-COVID-19 drugs in the top 200, indicating the high recall of EPT. By using Molecular Dynamics (MD) simulations, EPT further discoveries 7 novel compounds whose binding affinities are higher than that of the top-ranked known anti-COVID-19 drug, showcasing its powerful capabilities in drug discovery.